Chemotherapy

NICE guidance for access to advanced breast cancer treatment

NICE has published draft guidance today recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) as an option for treating HER-positive unresectable or metastatic breast cancer in adults, after two or more anti-HER2 therapies.

The decision means it will be the first time trastuzumab deruxtecan (also called Enhertu) has been commissioned for use in any European country. Up to 400 people will have immediate access to the treatment while more data is collected showing how much longer people who are taking it live, compared with people taking chemotherapy.

There is currently a lack of clinical trial data directly comparing trastuzumab deruxtecan with chemotherapy. However, the committee concluded that data from ongoing trials of trastuzumab deruxtecan and from NHS practice would help address the uncertainty about clinical effectiveness. Trastuzumab deruxtecan is therefore recommended for use in the Cancer Drugs Fund.

Current treatment for HER2‑positive unresectable or metastatic breast cancer includes anti‑HER2 therapies. After two or more anti‑HER2 therapies, the standard care is chemotherapy (such as capecitabine, vinorelbine or eribulin).

Meindert Boysen, Deputy Chief Executive and Director of the Centre for Health Technology Evaluation at NICE, said: “Unfortunately there is no cure for breast cancer that has spread to other parts of the body or that can’t be removed surgically.

The committee heard from patient experts who explained that, because of its side effects, people want to avoid having chemotherapies for as long as possible.

“Trastuzumab deruxtecan is a promising new treatment that has the potential to increase the length of time before the disease gets worse and how long people live overall.

"We’re therefore pleased that our work has allowed a deal to be struck between the company and NHS England supporting access to trastuzumab deruxtecan as an option in the CDF for people with this type of breast cancer.”

NHE Jan.Feb 21

NHE Jan/Feb 21

Creating a net zero NHS

NHE’s Jan/Feb 2021 edition focuses on the role of pharma working alongside the NHS, how we are working to digitise the health service and the ways in which the NHS can be involved in addressing the climate emergency.

Videos...

View all videos
BMC Whitepaper

Survey

How well do the NHS understand digital potential?

Recently we have been gathering primary data direct from those within the NHS on modernising NHS technology and the challenges faced around resource, training and service management.

Download the full whitepaper and read the full findings in our exclusive report to learn more.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all